Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × NSCLC × Bevacizumab × Clear all

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 22 Carcinoma, Non-Small-Cell Lung 7 Carcinoma, Hepatocellular 5 Breast Neoplasms 5 Ovarian Neoplasms 4 Lung Neoplasms 4 Colorectal Cancer Metastatic 3 Colonic Neoplasms 3 Carcinoma, Renal Cell 3 Adenocarcinoma of Lung 3 Rectal Neoplasms 2 Neoplasms 2 Brain Neoplasms 2 Adenocarcinoma, Bronchiolo-Alveolar 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Unresectable Hepatocellular Carcinoma 1 Surgical Wound Infection 1 Non-Squamous Non-Small Cell Lung Cancer 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 NSCLC 1 Melanoma 1 Liver Neoplasms 1 Kidney Neoplasms 1 Hypertension 1 Glioblastoma 1 Feasibility 1 Elderly Metastatic Colorectal Cancer Patients 1 Carcinoma, Ovarian Epithelial 1 Carcinoma 1

Interventions

pembrolizumab 1 osimertinib 1 icotinib 1 dacomitinib 1 camrelizumab 1 Radiofrequency Ablation 1 Gefitinib 1 Erlotinib Hydrochloride 1 Bevacizumab 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04575415 2020-10-20

BELLA

Guangdong Association of Clinical Trials

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡